Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains why clinical trials need to be inclusive and how the Health Equity Now initiative is working to recruit more diverse populations with diabetes.
The Health Equity Now initiative is working to make clinical trials more inclusive, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.
Transcript
The new ADA and EASD Type 1 Diabetes Guidance mentions that most data are from White European populations. What is being done to improve data collection from other groups?
One of the important aspects of our Health Equity Now is to think about, how can we ensure that clinical trials are broadly representative of the population, and particularly people who were at greatest risk for complications in the development of diabetes. So we're working to make available clinical trial opportunities for individuals and, particularly on the advocacy perspective, advocating for more inclusive recruitment of individuals for studies related to diabetes treatments.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More